{"protocolSection":{"identificationModule":{"nctId":"NCT05891171","orgStudyIdInfo":{"id":"ARC-25"},"organization":{"fullName":"Arcus Biosciences, Inc.","class":"INDUSTRY"},"briefTitle":"Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers","officialTitle":"A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","acronym":"ARC-25"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-26","studyFirstSubmitQcDate":"2023-05-26","studyFirstPostDateStruct":{"date":"2023-06-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-27","lastUpdatePostDateStruct":{"date":"2026-01-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Arcus Biosciences, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies."},"conditionsModule":{"conditions":["Advanced Cancer","Advanced Malignancies","Bladder Cancer","Cervical Cancer","Esophageal Cancer","Gastric Cancer","Gastroesophageal-junction Cancer (GEJ)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Non-Small Cell Lung Cancer (NSCLC)","Ovarian Cancer","Renal Cell Carcinoma (RCC)","Triple Negative Breast Cancer (TNBC)"],"keywords":["AB598","AB122","Zimberelimab"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation Cohort 1","type":"EXPERIMENTAL","description":"Participants will receive AB598 intravenous (IV) infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Dose Escalation Cohort 2","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Dose Escalation Cohort 3","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Dose Escalation Cohort 4","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Pharmacodynamic Cohort 1","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Pharmacodynamic Cohort 2","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Pharmacodynamic Cohort 3","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion once every 3 weeks","interventionNames":["Drug: AB598"]},{"label":"Dose Expansion Gastric/GEJ Cancer (phase 1b)","type":"EXPERIMENTAL","description":"Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab and FOLFOX (oxaliplatin, leucovorin, fluorouracil)","interventionNames":["Drug: AB598","Drug: Zimberelimab","Drug: Fluorouracil","Drug: Leucovorin","Drug: Oxaliplatin"]}],"interventions":[{"type":"DRUG","name":"AB598","description":"Administered as specified in the treatment arm","armGroupLabels":["Dose Escalation Cohort 1","Dose Escalation Cohort 2","Dose Escalation Cohort 3","Dose Escalation Cohort 4","Dose Expansion Gastric/GEJ Cancer (phase 1b)","Pharmacodynamic Cohort 1","Pharmacodynamic Cohort 2","Pharmacodynamic Cohort 3"]},{"type":"DRUG","name":"Zimberelimab","description":"Administered as specified in the treatment arm","armGroupLabels":["Dose Expansion Gastric/GEJ Cancer (phase 1b)"],"otherNames":["AB122"]},{"type":"DRUG","name":"Fluorouracil","description":"Administered as specified in the treatment arm","armGroupLabels":["Dose Expansion Gastric/GEJ Cancer (phase 1b)"]},{"type":"DRUG","name":"Leucovorin","description":"Administered as specified in the treatment arm","armGroupLabels":["Dose Expansion Gastric/GEJ Cancer (phase 1b)"]},{"type":"DRUG","name":"Oxaliplatin","description":"Administered as specified in the treatment arm","armGroupLabels":["Dose Expansion Gastric/GEJ Cancer (phase 1b)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 2 years"},{"measure":"Dose Escalation Cohorts: Number of Participants with Dose-Limiting Toxicities (DLTs)","timeFrame":"Up to 2 years"}],"secondaryOutcomes":[{"measure":"Area Under the Concentration-Time Curve from Administration (\"0\") to the Time That the Drug is No Longer Present in the Body (\"infinity\") (AUC 0-inf) in Whole Blood and Plasma","timeFrame":"Predose, Up to 4 hours post dose"},{"measure":"Maximum Concentration (Cmax) in Whole Blood and Plasma","timeFrame":"Predose, Up to 4 hours post dose"},{"measure":"Time to Maximum Concentration (Tmax) in Whole Blood and Plasma","timeFrame":"Predose, Up to 4 hours post dose"},{"measure":"Number of Participants Who Test Positive for Antidrug Antibodies (ADAs) to AB598","timeFrame":"Up to 2 years"},{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to 2 years"},{"measure":"Dose Expansion Cohort: Duration of Response (DOR)","timeFrame":"Up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidance\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Prior systemic radiation or whole brain radiation therapy must have been completed at least 4 weeks before investigational product (IP) administration. Other palliative radiotherapy must be completed 2 weeks before investigational product administration, if radiation therapy-related AEs have resolved to Grade â‰¤ 1.\n* Monotherapy-specific criteria for dose escalation and PD cohorts:\n\n  * Dose Escalation: Participants may have any pathologically confirmed advanced or metastatic solid tumor for which standard therapy has proven ineffective, intolerable, or is considered inappropriate.\n  * Pharmacodynamic Cohorts: Participants may have any pathologically confirmed advanced or metastatic solid tumors for which standard therapy has proven ineffective, intolerable, or is considered inappropriate. Participants must be able to undergo collection of a fresh frozen biopsy during screening, as well as provide an on-treatment fresh frozen biopsy.\n* Dose Expansion cohort criteria:\n\n  * Histologically confirmed, documented diagnosis of HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.\n  * No prior systemic treatment for locally advanced unresectable or metastatic disease.\n  * Cannot have progressed within 6 months of prior platinum-based chemotherapy for earlier stage disease.\n\nKey Exclusion Criteria:\n\n* Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of study\n* Underlying medical conditions or AEs that, in the investigator or sponsor's opinion, will make the administration of the study drugs hazardous\n* Any active or documented history of autoimmune disease including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment\n* History of trauma or major surgery within 28 days prior to the first dose of study drug\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressant medication during study treatment with certain protocol specified exceptions\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Arcus Biosciences","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Mayo Clinic Arizona","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Mayo Clinic Florida","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Lake City Cancer Care, LLC.","city":"Lake City","state":"Florida","zip":"32024","country":"United States","geoPoint":{"lat":30.18968,"lon":-82.63929}},{"facility":"Affinity Health Hope and Healing Cancer Services, LLC","city":"Hinsdale","state":"Illinois","zip":"60521","country":"United States","geoPoint":{"lat":41.80086,"lon":-87.93701}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Rutgers Cancer Institute of New Jersey","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Gabrail Cancer Center (GCC) Canton Facility","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"University Hospitals Cleveland Medical Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Next Oncology Dallas","city":"Irving","state":"Texas","zip":"75039","country":"United States","geoPoint":{"lat":32.81402,"lon":-96.94889}},{"facility":"Next Oncology Virginia","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Adelaide Cancer Research","city":"Adelaide","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Queen Elizabeth Hospital","city":"Adelaide","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"National Cheng Kung University Hospital","city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}}]},"referencesModule":{"seeAlsoLinks":[{"label":"ARC-25 - Public website","url":"https://trials.arcusbio.com/study/?id=ARC-25"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan \\[SAP\\], Clinical Study Report \\[CSR\\]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.\n\nFor more information, please visit our website.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"url":"https://trials.arcusbio.com/our-transparency-policy"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001749","term":"Urinary Bladder Neoplasms"},{"id":"D002583","term":"Uterine Cervical Neoplasms"},{"id":"D004938","term":"Esophageal Neoplasms"},{"id":"D013274","term":"Stomach Neoplasms"},{"id":"D000077195","term":"Squamous Cell Carcinoma of Head and Neck"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D010051","term":"Ovarian Neoplasms"},{"id":"D002292","term":"Carcinoma, Renal Cell"},{"id":"D064726","term":"Triple Negative Breast Neoplasms"}],"ancestors":[{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D001745","term":"Urinary Bladder Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D014594","term":"Uterine Neoplasms"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D004935","term":"Esophageal Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D013272","term":"Stomach Diseases"},{"id":"D002294","term":"Carcinoma, Squamous Cell"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D010049","term":"Ovarian Diseases"},{"id":"D000291","term":"Adnexal Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006058","term":"Gonadal Disorders"},{"id":"D000230","term":"Adenocarcinoma"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D001943","term":"Breast Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000719848","term":"zimberelimab"},{"id":"D005472","term":"Fluorouracil"},{"id":"D002955","term":"Leucovorin"},{"id":"D000077150","term":"Oxaliplatin"}],"ancestors":[{"id":"D014498","term":"Uracil"},{"id":"D011744","term":"Pyrimidinones"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005575","term":"Formyltetrahydrofolates"},{"id":"D013763","term":"Tetrahydrofolates"},{"id":"D005492","term":"Folic Acid"},{"id":"D011622","term":"Pterins"},{"id":"D011621","term":"Pteridines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D003067","term":"Coenzymes"},{"id":"D045762","term":"Enzymes and Coenzymes"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":false}